SynthesisDrug design, development and therapy2025
Transformative Role of Artificial Intelligence in Drug Discovery and Translational Medicine: Innovations, Challenges, and Future Prospects.
Synthesis in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress.Acta pharmacologica Sinica · 2026Review
- Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12.Journal of medicinal chemistry · 2026Review
- An Exploration of Machine Learning Methods in Human Biomonitoring.International journal of environmental research and public health · 2026Review
- Global Trends in Integrating Machine Learning (ML) with Model-Informed Drug Development (MIDD): A Bibliometric and Systematic Review (2015-2025).Pharmaceutics · 2026Review
- The impact of AI on modern oncology from early detection to personalized cancer treatment.NPJ precision oncology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The use of Artificial intelligence in drug discovery is changing the field of Medicine across the world today positively. In this review, the role of AI in each focus area for the improvement of the drug development process, and its relevance in translational medicine is discussed. Materials and Method: A systematic review was conducted by searching databases such as PubMed and Scopus, employing key terms like "AI" "drug discovery" "machine learning" "clinical trials" and "translational medicine." Inclusion criteria focused on peer-reviewed studies published between 2014 and 2024 that specifically addressed the role of AI in drug development. Data extraction involved categorizing findings based on different phases of drug discovery. Results: The findings reveal that the use of AI lowers costs, shortens the time required for drug development, and enhances the predictive capability. AI technologies play an essential role in molecular modeling, drug design and screening, and the efficient design of clinical trials. However, some of the issues that remain include the quality of available data, issues of interpretability of the models, and the more critical issue of ethical considerations that need collective efforts on the development of associate regulatory policies. Conclusion: AI holds immense potential to dramatically change and transform the process of drug discovery and translational medicine while promoting accurate prevention and cures. However, it is also important to understand how to work with existing problems to make the best use of AI in healthcare. The roles of AI technologies are likely to grow in the development of the medical future, provide patients with better results, and stimulate the innovations in the field of the drug creation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.